IMVT

Immunovant, Inc. - Common Stock (IMVT)

About Immunovant, Inc. - Common Stock (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

Details

Daily high

$29.83

Daily low

$28.12

Price at open

$29.78

52 Week High

$45.42

52 Week Low

$21.43

Market cap

6.2B

Dividend yield

Volume

1.1M

Avg. volume

1.4M

P/E ratio

-10.64

Immunovant, Inc. - Common Stock News